Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 4/20 | 0.44 |
| ▸ | MGAM | O43451 | 7/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 7/20 | 0.43 |
| ▸ | SI | P14410 | 7/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14494257 | 0.80 | ASAH1 (0.43) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL14470769 | 0.79 | ALDH1A1 (0.44) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL13253160 | 0.75 | ASAH1 (0.58) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL8221643 | 0.74 | ASAH1 (0.64) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL8221504 | 0.73 | ASAH1 (0.60) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL20150832 | 0.73 | ASAH1 (0.71) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL20150834 | 0.73 | ASAH1 (0.60) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL8218832 | 0.71 | ASAH1 (0.57) | ASAH1MGLLF12MGAMAMY1A | |
| SCHEMBL23368379 | 0.71 | NPC1 (0.49) | FAPKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL22101596 | 0.70 | ASAH1 (0.56) | ASAH1MGLLF12MGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ASAH1 31/4885MGLL 588/4885F12 660/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ASAH1 37/4885MGLL 1313/4885F12 394/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | ASAH1 42/4885MGLL 1323/4885F12 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.